Healthcare Webinars

Join us for an enlightening webinar where we'll address your burning questions about intimate wellness and treatment options. Dr. James and Dr. Salazar Valdes will provide valuable insights and discuss the latest advancements in the field. Register now to secure your spot!

The tumor microenvironment is a complex mix of cancer cells, immune cells, and other components that all play a part in tumor progression, metastasis, and therapy responses. Understanding the highly dynamic nature of the tumor microenvironment and the factors that influence those changes is essential for developing effective precision oncology therapies. Innovations in computational pathology and artificial intelligence, coupled with novel multiplex biomarker assays, are critical to fostering that understanding. Together, they are paving the way for scientists to better characterize the unique cancer cell populations, spatial relationships, and differences in immune responses in the tumor microenvironment.In this GEN webinar, Michael Downing, Senior Image Analysis Scientist at Ultivue, will review the state of the field and introduce Ultivue’s two core platform technologies: InSituPlex® assays, and its proprietary Spatial Image Analysis pipeline featuring UltiStacker.AI™ and UltiAnalyzer.AI™. He will also explain how these technologies work together to provide high confidence insights from tumor data for scientists developing precision cancer therapies.Topics covered in the webinar will include:How AI-supported spatial image analysis together with Ultivue’s InSituPlex assays deliver accurate and scalable insights into the biology of the tumor microenvironment.How Ultivue’s 12-plex assay verification demonstrates its readiness to provide a comprehensive view of the tumor microenvironment.A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

The field of biosimilars, which seeks to offer cost-effective alternatives to biologic drugs, has garnered significant attention in recent years. This report aims to provide an in-depth analysis of the biosimilar industry, tracing its evolution, examining its current market status over the past three years, and exploring future opportunities. Omnitrope's launch in 2006 was a pivotal moment for biosimilars, introducing them as viable options in healthcare. Initial regulatory hurdles were substantial, as biosimilar guidelines were nascent. The industry saw a turning point with the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) establishing a comprehensive approval pathway, which has since facilitated the entry of numerous biosimilars into the market. This report details the biosimilars approved up to the present, segmented by therapeutic application—such as treatments for growth hormone deficiency, anaemia, and autoimmune diseases. We highlight the first biosimilar moieties launched between 2021 and 2023, including their regulatory approvals and market impact on their reference drugs. The current regulatory environment and market dynamics for biosimilars are evaluated to understand their position in the healthcare landscape. We will analyze the upcoming biosimilars anticipated for launch in the upcoming years and their respective focused indications. The webinar offers a comprehensive analysis of the biosimilar landscape, from its inception to its future prospects. The increasing focus on research and development, combined with regulatory advancements, underscores the significant role biosimilars will play in enhancing patient access to affordable, effective treatments.

In the United States, public health and health care delivery have largely taken different and siloed approaches, with health care focused on the treatment of individuals and public health centered on the total population within a geographic region. Collaboration between the sectors is essential to advancing both health outcomes and equity—a lesson driven home during the COVID-19 pandemic. In a new webinar, Manatt Health will provide an in-depth look at the innovative ways California health agencies are working together to bridge the gap between public health and managed care health care delivery—and what other states can learn from the California model.

We are delighted to invite all from the HSE organisation, HealthSciencesLibrariesGroup and team members to attend the online launch of the #hselibrary strategy.

With presentations from experts at Atrium Wake Forest Baptist Health, this webinar will provide health system professionals with knowledge on how adopting a cochlear implant robotics program can help to position their health system's cochlear implant program as the program of choice for patients in their region. Our distinguished presenters, including an Associate Vice President of Regional Strategy and Planning and an Associate Professor of Otology/Neurotology, bring extensive expertise and firsthand experience to the discussion. They will delve into the strategic advantages, economic benefits, and clinical outcomes associated with integrating a cochlear implant robotics program into healthcare systems. Key highlights of the webinar include: 1. Strategic insights into positioning healthcare systems as leaders on patient access to advancements in implantable hearing technology 2. Analysis showcasing the economic case for cochlear implant robotics programs 3. Clinical evidence of robotic-assisted cochlear implantation vs. manual implantation techniques This webinar is tailored for professionals working within healthcare systems, particularly those involved in strategic planning, otology/neurotology, and related fields. Whether you're exploring innovative solutions to enhance patient care or seeking to stay ahead of industry trends, this webinar is an invaluable opportunity to gain knowledge and insights from leaders at the forefront of hearing healthcare. Don't miss out on this exclusive opportunity to discover the strategic, economic, and clinical rationale behind adopting a cochlear implant robotics program.

Enrollment, bonus payments, reputation — many growth opportunities hinge on Star Ratings. As payer organizations navigate a competitive landscape, it's crucial they take a proactive approach to improving their performance and the quality of care their members receive. Some organizations are streamlining their processes for identifying where members may experience gaps in care due to lag times, improper coding and lack of visibility to location and clinical status.In this interactive session, you'll learn how payers are forging partnerships to help: Identify members needing follow-up care based on HEDIS measuresUse real-time notifications to enable proactive interventionSend discharge summaries to network providers to support patient engagement for identified follow-up care and medication reconciliationUse HEDIS specifications to streamline provider performance monitoring and comprehensive reporting.

A career in the healthcare packaging industry provides an opportunity to positively impact patients and healthcare professionals everyday. It is also complex, challenging, and rapidly evolving. As the landscape of regulations and technology changes, it requires collaboration and innovation to meet end-user needs and solve critical problems.Join Oliver and three healthcare packaging professionals with diverse backgrounds as we tap into their expertise after years of experience in a healthcare packaging career.In this webinar the panelists will share:Best practices across different healthcare segments.Advice on navigating and influencing cross-functional teams.Trends our speakers see that are impacting healthcare packaging roles.Join Katherine Olson, Sr. Engineer, Global Packaging at Teleflex, Matt State, Package Engineering Manager at Olympus and Sydney Wilson, Consultant Packaging Engineer II at Network Partners, as they share their experiences as Healthcare Packaging Engineers in this FREE webinar.Speakers:Katherine Olson Sr. Engineer, Global Packaging Teleflex LinkedInSydney Wilson Consultant Packaging Engineer II Network Partners LinkedInMatt State Package Engineering Manager Olympus LinkedInHOST: Haley Schrauben Group Product Manager, Medical Devices Oliver Healthcare Packaging LinkedIn

Oestrogen receptor 1 (ER/ESR1) mutations have arisen as crucial biomarkers for endocrine therapy resistance in ER positive metastatic breast cancer. Detecting these mutations is key for understanding acquired resistance during treatment.APIS will be joined by SensID GmbH to deliver this FREE educational webinar on ESR1 mutations and the importance of their accurate and sensitive detection.Gain insights into: - ESR1 mutations significance in breast cancer and their role in endocrine therapy resistance - APIS ESR1 Mutations Kit, an accessible method to detect ESR1 mutations - SensID ESR1 reference set to ensure accurate detection of mutations in cell-free DNA (cfDNA)Have your questions answered by experts in gene mutation assay development and validation!

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations from the Society for Immunotherapy of Cancer & the International Bladder Cancer Group. Join the webinar on March 18, 2024, from 4-5 p.m. CST to discuss the publication in-depth with experts.